How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?
In the ADVOCATE trial, patients were not re-dosed with rituximab.
Community PollStarted
Once approved, will you recommend avacopan to patients who receive rituximab induction and maintenance therapy for AAV?
32 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Rheumatology · Director, Vasculitis Clinical Research Consortium
Answered on
The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:
The data from ADVOCATE indicate that patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) treated with avacopan 30 mg twice daily and prednisone placebo were able to achieve remission w...
Join for free or sign in to see the full answer